Search
Etomidate
go.drugbank.com/drugs/DB00292ApprovedInvestigationalIt has been proposed as an induction anesthetic.
Synonyms: (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate, R-(+)-ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylateProducts: HYPNOMIDATE 2 MG /10 ML AMPUL, 5 ADET, ETOMIDATE-LIPURO INJECTION 20 mg/10 mlCiprofibrate
go.drugbank.com/drugs/DB09064ApprovedInvestigationalWithdrawnProducts: MODALIM TABLET 100 mg, CIPROFIBRATO 100 MG TABLETASBurosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalSome adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss [L2346]. … Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic
Products: CRYSVITA® SOLUTION FOR INJECTION 10 MG/ML, CRYSVITA 10 MG SOLUTION FOR INJECTIONCabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigationalCabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. … It was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSynonyms: 1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)Filgrastim
go.drugbank.com/drugs/DB00099ApprovedInvestigationalIt has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. … [L40773] A long-acting, pegylated G-CSF, [pegfilgrastim], was made available to increase the duration of action of the drug.
Products: NIVESTIM 30 MU/0,5 ML SC/IV ENJEKSIYONLUK ÇÖZELTI IÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET, LEUKOPLUS 30 MIU/ML SC/IV ENJEKSIYON/INFUZYON ICIN COZ. ICEREN FLAKON, 10 ADETRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalBYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. … [A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.
Products: LUCENTIS® 10 MG /ML SOLUCION INYECTABLE, LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGEVinblastine
go.drugbank.com/drugs/DB00570ApprovedInvestigationalAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: VINCABLAS® 10 MG/VIAL, VINBLASTINA SULFATO 10 MGPramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalIt was first approved by the FDA in 1997 [L5882]. … The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861].
Products: PACTO 0,5 MG TABLET, 100 ADET, PACTO 1,5 MG TABLET, 100 ADETGadobutrol
go.drugbank.com/drugs/DB06703ApprovedInvestigationalGadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties...
Synonyms: gadolinium(III) 2,2',2''-(10-((2R,3S )-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetateProducts: GADOVIST 1MMOL/ML PREFILLED SYRINGE 5.0 ML, GADOVIST 1.0 MMOL/ML ENJEKSIYONLUK COZELTI ICEREN SISE, 30 MLHyaluronic acid
go.drugbank.com/drugs/DB08818ApprovedInvestigationalVet approvedHyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934.
Mixtures: Ascorbyl Palmitate 2% / Hyaluronic Acid Sodium Salt 0.2% / Niacinamide 5% / Tretinoin 0.025%, Hyaluronic Acid Sodium Salt 1% / Tacrolimus 0.1% / Urea 20%Products: HIALSEC 4 MG/ML SOLUCIÓN OFTÁLMICA X 10 ML, EYESTIL GOZ DAMLASI 10 ML